Omnicell, Inc.

How big is Omnicell, Inc.?

As of Jun 18, Omnicell, Inc. has a market capitalization of $1.62 billion, with recent net sales of $1.14 billion and a net profit of $21.18 million over the last four quarters.

Market Cap: As of Jun 18, Omnicell, Inc. has a market capitalization of 1,616.45 million, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Omnicell, Inc. reported net sales of 1,135.76 million and a net profit of 21.18 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 1,243.31 million, while total assets were reported at 2,120.96 million.

What does Omnicell, Inc. do?

Omnicell, Inc. offers automation and analytics software for medication and supply management in the healthcare sector. As of March 2025, it reported net sales of $270 million and a net loss of $7 million, with a market cap of approximately $1.62 billion.

Overview: <BR>Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management, operating within the Computers - Software & Consulting industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 270 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,616.45 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 78.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.05 <BR>Return on Equity: 1.79% <BR>Price to Book: 1.29<BR><BR>Contact Details: <BR>Address: 590 E Middlefield Rd, MOUNTAIN VIEW CA: 94043-4008 <BR>Tel: 1 650 2516100 <BR>Fax: 1 650 2516266 <BR>Website: https://www.omnicell.com/

Should I buy, sell or hold Omnicell, Inc.?

Who are in the management team of Omnicell, Inc.?

As of March 2022, the management team of Omnicell, Inc. includes Randall Lipps as Chairman, President, and CEO, with James Judson as Lead Independent Director and other board members including Robin Seim, Joanne Bauer, Vance Moore, and Mark Parrish.

As of March 2022, the management team of Omnicell, Inc. includes Mr. Randall Lipps, who serves as the Chairman of the Board, President, and Chief Executive Officer. Other members of the Board of Directors include Mr. James Judson as the Lead Independent Director, Mr. Robin Seim as a Director, and independent directors Ms. Joanne Bauer, Mr. Vance Moore, and Mr. Mark Parrish.

Is Omnicell, Inc. overvalued or undervalued?

As of August 15, 2025, Omnicell, Inc. is considered very attractive due to its undervaluation indicated by a PEG ratio of 0.21 and a P/E ratio of 78, despite struggling with significant declines in returns compared to the S&P 500.

As of 15 August 2025, the valuation grade for Omnicell, Inc. moved from fair to very attractive, indicating a shift towards a more favorable assessment. The company appears undervalued, particularly given its PEG ratio of 0.21, which suggests strong growth potential relative to its price, alongside a P/E ratio of 78 and an EV to EBITDA of 16.81. In comparison, its peer Pegasystems, Inc. has a P/E of 48.13, while AppFolio, Inc. stands at 51.16, highlighting Omnicell's relatively lower valuation metrics.<BR><BR>Despite the attractive valuation, Omnicell has struggled with returns, showing a year-to-date decline of 28.57% compared to a 12.22% gain in the S&P 500, and a staggering 66.62% drop over three years against the benchmark's 70.41% rise. This stark contrast in performance underscores the potential for recovery in the stock, aligning with its current undervaluation status.

Is Omnicell, Inc. technically bullish or bearish?

As of October 31, 2025, Omnicell, Inc. exhibits a neutral technical trend with mixed indicators, showing mild bullishness on weekly and monthly MACD but short-term bearishness in daily moving averages, while significantly underperforming the S&P 500 with year-to-date and one-year returns of -22.51% and -29.11%, respectively.

As of 31 October 2025, the technical trend for Omnicell, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. However, the daily moving averages are mildly bearish, indicating some short-term weakness. The Bollinger Bands show a mildly bullish signal on the weekly chart but bearish on the monthly. The KST is bullish on the weekly but bearish on the monthly, and Dow Theory indicates no trend in both weekly and monthly timeframes. <BR><BR>In terms of performance, Omnicell has underperformed the S&P 500 significantly over longer periods, with a year-to-date return of -22.51% compared to the S&P 500's 16.30%, and a one-year return of -29.11% versus 19.89% for the index.